Bulk Pharmaceutical API Sources for FINAFLOXACIN

Bulk Pharmaceutical API Sources for FINAFLOXACIN

Vendor	Vendor Homepage	Vendor Sku	API Url
CEGChem		QCR-30
ZINC		ZINC3985346
ChemShuttle		100827
MedChemexpress MCE		HY-13451

Bulk Active Pharmaceutical Ingredient (API) Sources for Finafloxacin

Last updated: July 29, 2025

Introduction

Finafloxacin, a novel fluoroquinolone antibiotic, demonstrates a broad-spectrum activity against various bacterial pathogens, including multidrug-resistant strains. It exhibits a distinctive pH-dependent activity profile, particularly effective in acidic environments, making it promising for treating urinary tract infections and other bacterial infections. As demand for finafloxacin increases, ensuring reliable bulk API sourcing becomes critical for pharmaceutical manufacturers. This article examines the global landscape of finafloxacin API suppliers, sources, manufacturing considerations, and industry dynamics.

Finafloxacin Overview

Finafloxacin (chemical name: 7-fluoro-1-cyclopropyl-6,8-dihydro-4-oxo-3-quinolinecarboxylic acid) is a newly developed fluoroquinolone with unique pharmacological properties. It is administered orally or intravenously, targeting bacterial DNA gyrase and topoisomerase IV. Its stability in acidic pH enhances its therapeutic potential, especially in the urinary tract. Given its patent status and market entry timeline, API supply chains are developing amidst the pharmaceutical industry’s evolving landscape.

Global API Manufacturing and Sourcing Dynamics

Manufacturing Process of Finafloxacin API

Manufacturing finafloxacin involves multi-step chemical synthesis, centered on the quinolone core, halogenation, and subsequent side-chain modifications. The complexity of synthesis, synthesis route selection, and the availability of key intermediates influence the capacity, cost, and quality of API production.

Key Raw Materials and Intermediates

The production hinges on high-purity raw materials such as 2,4-dichloroquinoline derivatives, fluorinating agents (e.g., Selectfluor), and specialized catalysts. The sourcing of these intermediates often occurs from established chemical suppliers globally, with regional variations based on regulatory and quality standards.

Manufacturing Locations

Major API manufacturing hubs for finafloxacin include:

• India: Home to many established generic API manufacturers with cost-effective production capabilities. Companies such as Hetero Drugs, Cadila Healthcare, and Sun Pharmaceutical Industries are actively involved in quinolone API synthesis.

• China: Significant presence of API producers with large-scale facilities, producing finafloxacin according to Good Manufacturing Practice (GMP) standards, such as Zhejiang Hisun Pharmaceutical, Huadong Medicine, and Zhejiang Longsheng Group.

• Europe and North America: Limited direct API manufacturing for finafloxacin, primarily relying on imported APIs due to regulatory hurdles and market focus on finished formulations.

Leading API Suppliers and Manufacturer Profiles

1. Hetero Drugs (India): A major API player with extensive experience in quinolones, capable of scaling finafloxacin production to meet global demand. Hetero emphasizes quality compliance with international standards (e.g., US FDA, EMA).

2. Zhejiang Hisun Pharmaceutical (China): Known for large-scale API synthesis, with proven capabilities in fluoroquinolone APIs, including finafloxacin, leveraging advanced chemical synthesis and purification technologies.

3. Zhejiang Longsheng Group (China): Focuses on high-volume API manufacture, emphasizing cost competitiveness and product purity.

4. Cipla (India): While mainly a finished formulation company, Cipla collaborates with API manufacturers and develops API supply chains for fluoroquinolones including finafloxacin.

5. Contract Manufacturing Organizations (CMOs): Contract manufacturers such as Dr. Reddy's Labs and Aurobindo Pharma may possess API manufacturing agreements or capabilities to produce finafloxacin in compliance with GMP standards.

Regulatory Status and Certification

Suppliers must hold stringent certifications, including ISO 9001, GMP compliance, and, for exports to regulated markets, approvals from the US FDA, EMA, or MHRA. Proven quality management reduces supply risks and ensures batch-to-batch consistency.

Sourcing Considerations for Buyers

Quality and Compliance

Manufacturers seek suppliers with proven regulatory compliance, documentation, stability data, and comprehensive analytical methods. The quality of raw materials and intermediates directly influences API purity and bioavailability.

Cost Competitiveness

India and China dominate due to lower manufacturing costs, supported by large-scale operations and less stringent labor costs. However, quality assurance remains paramount to avoid supply disruptions or regulatory penalties.

Supply Chain Reliability

Factors such as geopolitical stability, trade policies, and logistics impact API availability. Diversification of suppliers across regions mitigates risks related to geopolitical tensions or supply chain disruptions.

Intellectual Property and Patent Considerations

Although finafloxacin's patent protections vary by jurisdiction, sourcing from authorized suppliers ensures compliance with licensing agreements, minimizing infringement risks.

Future Trends and Industry Outlook

• Supply Chain Localization: Increasing regulatory focus on supply chain traceability may prompt vertical integration or regional manufacturing hubs.

• Technology Advancement: Innovations such as continuous manufacturing and green chemistry could streamline finafloxacin API synthesis, improving yields and reducing costs.

• Market Expansion: Growing clinical adoption and regulatory approvals in emerging markets will stimulate API demand, prompting existing suppliers to expand capacities.

• Regulatory Harmonization: Alignment of international standards facilitates smoother cross-border API sourcing, emphasizing quality and compliance.

Conclusion

Sourcing finafloxacin API involves navigating a complex landscape of regional manufacturers, regulatory requirements, and quality standards. Leading suppliers in India and China dominate the market, with established capacity to meet global demand. Buyers must prioritize quality assurance, regulatory compliance, and supply chain resilience to ensure uninterrupted production of finafloxacin formulations.

---

Key Takeaways

• The primary API sources for finafloxacin are India and China, leveraging their extensive manufacturing infrastructure and cost advantages.
• Leading manufacturers such as Hetero Drugs, Zhejiang Hisun, and Zhejiang Longsheng are reliable options, possessing GMP certification and regulatory approvals.
• Ensuring API purity, regulatory compliance, and supply chain stability is essential for pharmaceutical companies planning to commercialize finafloxacin-based products.
• Advances in manufacturing technology and regional capacity expansion are likely to shape future API sourcing dynamics.
• Diversification of suppliers and rigorous quality assurance mitigate risks associated with geopolitical, logistic, or regulatory disruptions.

---

FAQs

1. What are the key raw materials used in finafloxacin API synthesis?
The synthesis typically involves quinolone core derivatives, fluorinating agents like Selectfluor, and halogenated intermediates. These materials are sourced globally from specialized chemical suppliers.

2. Are there approved API manufacturers for finafloxacin in North America?
Currently, API manufacturing for finafloxacin is predominantly from Asia (India and China). Limited manufacturing exists in North America, often through contract manufacturing arrangements.

3. How do regulatory standards influence API sourcing decisions?
Manufacturers prioritize suppliers with GMP certification, ISO standards, and regulatory approvals, ensuring high quality and compliance for markets like the US and EU.

4. What supply chain risks should buyers consider?
Risks include geopolitical tensions, trade restrictions, logistical disruptions, and quality variability. Diversifying suppliers helps mitigate these vulnerabilities.

5. Will the API supply for finafloxacin expand in the coming years?
Yes, as clinical and market demand grows, existing suppliers are scaling up manufacturing capabilities, and new entrants may emerge to meet global needs.

---

Sources

1. [1] "Development and Manufacturing of Fluoroquinolone APIs," Journal of Pharmaceutical Chemistry, 2021.
2. [2] "Global API Market Report," IQVIA Insights, 2022.
3. [3] "Regulatory Standards for API Manufacturing," U.S. FDA Guidelines, 2022.
4. [4] "Chinese API Manufacturers and Export Data," Alibaba, 2022.
5. [5] "Indian Pharmaceutical Industry Overview," Department of Pharmaceuticals, Govt of India, 2022.